TABLE 2.
Characteristic | Prevalence ratio | (95% CI) | p value |
---|---|---|---|
Race/Ethnicity | |||
Black | 0.9 | (0.8–0.9) | <0.01 |
White (reference group) | 1.0 | ||
Hispanic | 1.0 | (0.9–1.2) | 0.70 |
Other/Unknown | 1.1 | (1.0–1.2) | 0.07 |
Age group (yrs) § | |||
13–24 | 0.8 | (0.7–0.9) | <0.01 |
25–34 | 0.9 | (0.7–1.0) | 0.17 |
35–44 | 0.9 | (0.8–1.0) | 0.23 |
45–54 | 0.9 | (0.9–1.1) | 0.33 |
≥55 (reference group) | 1.0 | ||
Disease stage at diagnosis ¶ | |||
1 | 0.8 | (0.7–0.9) | <0.01 |
2 | 0.9 | (0.8–1.0) | 0.02 |
3 (reference group) | 1.0 | ||
Unknown | 0.8 | (0.8–0.9) | <0.01 |
Sex | |||
Male | 1.0 | ||
Female | 1.0 | (0.9–1.1) | 0.97 |
Abbreviation: CI = confidence interval.
Retained in care defined as having at least two laboratory tests (CD4+ or viral load) at least 3 months apart during 4–15 months after diagnosis.
Among persons residing in Georgia and having a positive Western Blot or viral load based on surveillance data reported during 2010. Viral suppression defined as viral load <200 on the basis of most recent test during 4–15 months after diagnosis. Only includes persons with their sex recorded at birth.
Age based on the person’s age at year’s end 2010.
Based on first recorded CD4+ cell count ≤3 months after diagnosis. Defined as stage 1: CD4+ count ≥500 cells/μL or CD4+ percentage of total lymphocytes ≥29; stage 2: CD4+ count of 200–499 cells/μL or CD4+ percentage of total lymphocytes of 14–28; and stage 3: CD4+ count of <200 cells/μL or CD4+ percentage of total lymphocytes of <14.